You are here

American Journal of Cancer Prevention

ISSN (Print): 2328-7314

ISSN (Online): 2328-7322

Editor-in-Chief: Nabil Abdel-Hamid

Website: http://www.sciepub.com/journal/AJCP

   

Article

Squamous Cell Carcinoma of the Renal Pelvis: Rare Case Report

1Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran


American Journal of Cancer Prevention. 2016, 4(4), 54-56
doi: 10.12691/ajcp-4-4-2
Copyright © 2016 Science and Education Publishing

Cite this paper:
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi. Squamous Cell Carcinoma of the Renal Pelvis: Rare Case Report. American Journal of Cancer Prevention. 2016; 4(4):54-56. doi: 10.12691/ajcp-4-4-2.

Correspondence to: Edris  Sadeghi, Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email: sadeghi_mkn@yahoo.com

Abstract

Primary squamous cell carcinoma (SCC) of the kidney is an extremely rare entity representing only 0.5-15% of all urothelial cancers. Herein, we reported a rare case of renal cell carcinoma with SCC extended to the pelvis. A 56 year-old female patient referred to the oncology clinic with complaints of pain in the right flank. The CT showed a hypodense renal mass of size approximately 2 × 2.1 cm in the upper pole of the right kidney. High grade urothelial carcinoma and squamous cell carcinoma extended to renal capsule, but not pass to perirenal fat. Vascular invasion was present, but perineural invasion was not seen. Ureteral margin was free of tumor. Biopsy showed one hilar lymph node involved with tumor in the near right kidney. A few slightly stones smaller than normal 0.4 × 0.9 cm can be seen in the calyx of the asymptomatic hydronephrosis of left kidney. SCC is one of the rare histological tissues in the kidney and hydronephrosis is the most common complaints in more patients with this malignancy.

Keywords

References

[1]  Jain A, Mittal D, Jindal A, Solanki R, Khatri S, Parikh A, et al. Incidentally detected squamous cell carcinoma of renal pelvis in patients with staghorn calculi: caseseries with review of the literature. ISRN Oncol. 2011; 2011: 620574.
 
[2]  Bandyopadhyay R, Biswas S, Nag D, Ghosh AK. Squamous cell carcinoma of the renal pelvis presenting as hydronephrosis. J Cancer Res Ther. 2010;6(4):537-9.
 
[3]  Karabulut A, Emir L, Gonultas M, Incel N, Germiyanoglu C and Erol D. Squamous cell carcinoma located in the renal caliceal system: A case report and review of the literature. Turkish J of Cancer. 2002;32(1):20-4.
 
[4]  O. Odabas, M. Karakok, Y. Yilmaz, M. K. Atilla, E. Akman, S. Aydin, et al. Squamous cell carcinoma of kidney. Eastern Journal of Medicine. 2000;5(1):35-6.
 
[5]  Lanjewar SM, Bodade RM, Bansod AN, Kulkarni A. Primary squamous cell carcinoma of kidney: a case report. Int Surg J.2015;2(1):82-4.5.
 
Show More References
[6]  N. Talwar, P. Dargan, MP Arora, A. Sharma, and AK Sen. Primary squamous cell carcinoma of the renal pelvis masquerading as pyonephrosis: a case report. Indian Journal of Pathology and Microbiology. 2006;49(3):418-20.
 
[7]  Lee TY, Ko JF, Wan YL, Cheng YF, Yang BY, Huang DL, et al. Renal squamous cell carcinoma: CT findings and clinical significance. Abdom Imaging. 1998; 23(2):203-8.
 
[8]  Li MK, Cheung WL. Squamous cell carcinoma of the kindey. J Urol. 1987;138(2):269-71.
 
[9]  Kose F, Bal N, Ozyilkan O. Squamous cell carcinoma of the renal pelvis. Med Oncol. 2009;26(1):103-4.
 
Show Less References

Article

The Role of Endocan in the Development of Hepatocellular Carcinoma

1Department of Hepatobiliary Surgery, Bishan District People's Hospital, Chongqing, China

2Department of Hepatobiliary, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

3Department of Hepatobiliary and Thoracic Surgery, Tongliang District People's Hospital, Chongqing, China


American Journal of Cancer Prevention. 2016, 4(4), 57-63
doi: 10.12691/ajcp-4-4-3
Copyright © 2017 Science and Education Publishing

Cite this paper:
Xiao-hong Zhou, Xing Lai, De-an Mu, Jian-ping Gong, Qing-gang Yin. The Role of Endocan in the Development of Hepatocellular Carcinoma. American Journal of Cancer Prevention. 2016; 4(4):57-63. doi: 10.12691/ajcp-4-4-3.

Correspondence to: Qing-gang  Yin, Department of Hepatobiliary and Thoracic Surgery, Tongliang District People's Hospital, Chongqing, China. Email: 260426944@qq.com

Abstract

Endocan is a dermatan sulfate proteoglycan, constituted of a core protein with 165 amino acids and a single dermatan sulfate chain covalently linked to the serine 137. It is mainly expressed by the activated endothelial cell and regulated by various cytokines and growth factors. In hepatocellular carcinoma (HCC), the expression of endocan increases significantly, and it can induce tumorigenesis and promote the tumor progression. Endocan involves in the proliferation of HCC cell, angiogenesis, metastasis and immunity via a variety of complicated pathways, which cover the regulation of hepatic inflammation-fibrosis-cancer (IFC) axis through nuclear factor-kappa B (NF-кB), modulating cell cycle, interaction with vascular endothelial growth factors (VEGF), the collapse of cell-cell junction, inhibiting of lymphocyte function associated antigen-1 /intercellular adhesion molecule-1(LFA-1/ICAM-1) and changing of tumor microenvironment. Therefore, it is a potential marker and promising therapy target of HCC.

Keywords

References

[1]  Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell specific molecule expressed in lung and regulated by cytokines. J Biol Chem, 1996; 271(34): 20458-64.
 
[2]  Béchard D, Gentina T, Delehedde M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem, 2001; 276(51): 48341-9.
 
[3]  Delehedde M, Devenyns L, Maurage CA, et al. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol, 2013; 2013: 705027.
 
[4]  Mihajlovic DM, Lendak DF, Brkic SV, et al. Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res, 2014; 93: 92-7.
 
[5]  Tsai JC, Zhang J, Minami T, et al. Cloning and characterization of the human lung endothelial-cell-specific molecule-1 promoter. J Vasc Res, 2002; 39(2): 148-59.
 
Show More References
[6]  Cong R, Jiang X, Wilson CM, et al. Hhex is a direct repressor of endothelial cell-specific molecule 1 (ESM-1). Biochem Biophys Res Commun, 2006; 346(2): 535-45.
 
[7]  Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta, 2006; 1765(1): 25-37.
 
[8]  Sarrazin S, Lyon M, Deakin JA, et al. Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan. Glycobiology, 2010; 20(11): 1380-8.
 
[9]  Aitkenhead M, Wang SJ, Nakatsu MN, et al. Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res, 2002; 63(2): 159-71.
 
[10]  Depontieu F, Grigoriu BD, Scherpereel A, et al. Loss of Endocan tumorigenic properties after alternative splicing of exon 2. BMC Cancer, 2008; 8: 14.
 
[11]  Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res, 2000; 37(5): 417-25.
 
[12]  Wellner M, Herse F, Janke J, et al. Endothelial cell specific molecule-1--a newly identified protein in adipocytes. Horm Metab Res, 2003; 35(4): 217-21.
 
[13]  Zhang SM, Zuo L, Zhou Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem, 2012; 87(3): 172-8.
 
[14]  Grigoriu BD, Depontieu F, Scherpereel A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res, 2006; 12(15): 4575-82.
 
[15]  Roudnicky F, Poyet C, Wild P, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res, 2013; 73(3): 1097-106.
 
[16]  Maurage CA, Adam E, Mineo JF, et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol, 2009; 68(6): 633-41.
 
[17]  Leroy X, Aubert S, Zini L, et al. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology, 2010; 56(2): 180-7.
 
[18]  Rennel E, Mellberg S, Dimberg A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res, 2007; 313(7): 1285-94.
 
[19]  Ji NY, Kim YH, Jang YJ, et al. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci, 2010; 101(10): 2248-53.
 
[20]  Kang YH, Ji NY, Lee CI, et al. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids, 2011; 40(3): 1003-13.
 
[21]  Scherpereel A, Depontieu F, Grigoriu B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med, 2006; 34(2): 532-7.
 
[22]  De Freitas Caires N, Legendre B, Parmentier E, et al. identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal, 2013; 78-79: 45-51.
 
[23]  Hatfield KJ, Lassalle P, Leiva RA, Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology, 2011; 16(6): 351-6
 
[24]  Gerritsen ME, Tomlinson JE, Zlot C,et al. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol, 2003; 140(4): 595-610.
 
[25]  Abid MR, Yi X, Yano K, et al. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res, 2006; 72(3): 136-45.
 
[26]  Zhao X, Ramsey KE, Stephan DA, et al. Gene aand protein expression changes in human trabecular meshwork cells treated with transforming growth factor-beta. Invest Ophthalmol Vis Sci, 2004; 45(11): 4023-34.
 
[27]  Lee W, Ku SK, Kim SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol, 2014; 229(5): 620-30.
 
[28]  Kim JH, Park MY, Kim CN, et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1α in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep, 2012; 28(5): 1701-8.
 
[29]  Ozaki K, Toshikuni N, George J, et al. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer, 2014; 5(3): 221-30.
 
[30]  Elsharkawy AM, Mann DA. Nuclear factor-kappa B and the hepatic inflammation-fibrosis-cancer axis. Hepatology, 2007; 46(2): 590-7.
 
[31]  Connolly MK, Bedrosian AS, Mallen-St Clair J, et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest, 2009; 119(11): 3213-25.
 
[32]  Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut, 2006; 55(3): 415-24.
 
[33]  Carrillo LM, Arciniegas E, Rojas H, et al. Immunolocalization of endocan during endothelial-mesenchymal transition process. Eur J Histochem, 2011; 55(2): e13.
 
[34]  Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to mesenchymal transition contributes to cardiac fibrosis. Nat Med, 2007; 13(8): 952-61.
 
[35]  Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kindney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol, 2008; 19(12): 2282-7.
 
[36]  Hashimoto N, , Imaizumi K, et al. Endothelial mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol, 2010; 43(2): 161-72.
 
[37]  Zhang SH, Wen KM, Wu W, et al. Efficacy of HGF carried by ultrasound microbubble-cationic nano-liposomes complex for treating hepatic fibrosis in a bile duct ligation rat model, and its relationship with the diffusion-weighted MRI parameters. Clin Res Hepatol Gastroenterol, 2013; 37(6): 602-7.
 
[38]  Wang ZX, Wang ZG, Ran HT, et al. The treatment of liver fibrosis induced by hepatocyte growth factor-directed, ultrasound-targeted microbubble destruction in rats. Clin Imaging, 2009; 33(6): 454-61.
 
[39]  Li S, Wang L, Wang C, et al. Detection on dynamic changes of endothelial cell specific molecule acute rejection after renal transplantation. Urology, 2012; 80(3): 738.e1-8.
 
[40]  Balta I, Balta S, Koryurek OM, et al. Serum ednocan levels as a marker of disease activity in patients with Behcet disease. J Am Acad Dermatol, 2014; 70(2): 291-6.
 
[41]  Adekola H, Romero R, Chaemsaithong P, et al. Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes. J Matern Fetal Neonatal Med, 2014; 11: 1-35.
 
[42]  Balta S, Mikhailidis DP, Demirkol S, et al. Endocan-a novel inflammatory indicator in newly diagnosised patients with hypertension: a pilot study. Angiology, 2014; 65(9): 773-7.
 
[43]  Iwakiri Y. endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int. 2012; 32(2): 199-213.
 
[44]  Lin HC, Huang YT, Yang YY, et al. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertension. J Gastroenterol Hepatol, 2014; 29(5): 1073-82.
 
[45]  Rocha SF, Schiller M, Jing D. Esm 1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res, 2014; 115(6): 581-90.
 
[46]  Tok D, Ekiz F, Basar O. Serum endocan levels in patients with chronic liver disease. Int J Clin Exp Med, 2014; 7(7): 1802-7.
 
[47]  Zoil M, Sutton A, Calderaro J, et al. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol, 2013; 59(6): 1264-70.
 
[48]  Scherpereel A, Gentina T, Grigoriu B. Overexpression of endocan induces tumor formation. Cancer Res, 2003; 63(18): 6084-9.
 
[49]  Chen LY, Liu X, Wang SL, et al. over-expression of the endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumor invasion. J Int Med Res, 2010; 38(2): 498-510.
 
[50]  Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci, 2009; 54(2): 389-94.
 
[51]  Hu J, Xu Y, Shen ZZ, et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol, 2009; 135: 1359-67.
 
[52]  Minata M, Harada KH, Kudo M, et al. The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection. Oncology, 2013; 84: 75-81.
 
[53]  Tseng PL, Tai MH, Huang CC, et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol, 2008; 98: 349-57
 
[54]  Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellualr carcinoma: systematic review and meta-analysis. Br J Cancer, 2009; 100(9): 1385-92.
 
[55]  Zhan P, Qian Q, Yu LK. Prognostic significance of vascular endothelial growth factor expressiom in hepatocellular carcinoms tissue: a meta-analysis. Hepatobiliary Surg Nutr, 2013; 2(3): 148-55.
 
[56]  Takahashi S. Vascular endothelial growth factor(VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull, 2011; 34(12): 1785-8.
 
[57]  del Toro R, Prahst C, Mathiver T, et al. Identification and functional analysis of endothelial tip cell-enriched gene. Blood, 2010; 116(19): 4025-33.
 
[58]  De Smet F, Segura I, De Bock K, et al. Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol, 2009; 29(5): 639-49.
 
[59]  Strasser GA, Kaminker JS, Tesssier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as mediator of tip cell morphology and branching. Blood, 2010; 115(24): 5102-10.
 
[60]  García-Román J, Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett, 2013; 335(2): 259-69.
 
[61]  Mouta Carreira C, Nasser SM, di Tomaso E. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res, 2001; 61(22): 8079-84.
 
[62]  Shin JW, Huggenberger R, Detmar M. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood, 2008; 112(6): 2318-26.
 
[63]  Anderson ME, Siahaan TJ. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides, 2003; 24(3): 487-501.
 
[64]  Herter J, Zarbock A. Integrin Regulation during Leukocyte Recruitment. J Immunol, 2013; 190(9): 4451-7.
 
[65]  Takeichi T, Mocevicius P, Deduchovas O, et al. αL β2 integrin is indispensable for CD8+ T-cell recruitment in experimental pancreatic and hepatocellular cancer. Int J Cancer, 2012; 130(9): 2067-76.
 
[66]  Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol, 2001; 167(6): 3099-106.
 
[67]  Leonardi GC, Candido S, Cervello M, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol, 2012; 40(6): 1733-47.
 
[68]  Lin F, Wang N, Zhang TC. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life, 2012; 64(9): 717-23.
 
[69]  Zeisberg EM, Potenta S, Xie L, et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res, 2007; 67(21): 10123-8.
 
[70]  Nault JC, Goouyot E, Laguillier C, et al. Serum proteoglycans as prognostic biomarker of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev, 2013; 22(8): 1343-52.
 
[71]  Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol, 2008; 15(5): 1375-82.
 
[72]  Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer, 2004; 101(4): 796-802.
 
[73]  Poon RT, Fan ST, Lo CM, et al. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg, 2007; 245(1): 51-8.
 
[74]  Yamamoto J, Kosuge T, Saiura A, et al. Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. Jpn J Clin Oncol, 2007; 37(4): 287-95.
 
[75]  Xiang ZL, Zeng ZC, Fan J, et al. The expression of HIF-1α in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep, 2012; 39(2): 2021-9.
 
Show Less References

Article

Surgical Treatment of Huge Primary Retroperitoneal Tumor: A Report of 14 Cases

1Department of General Surgery, The Second People's Hospital of Jiulongpo District, Chong Qing, China

2Department of Hepatobiliary, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

3Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China


American Journal of Cancer Prevention. 2016, 4(4), 64-69
doi: 10.12691/ajcp-4-4-4
Copyright © 2017 Science and Education Publishing

Cite this paper:
Zheng-jun Cheng, Qian Cheng, Jian-ping Gong, Chan Qiu, Da-xing Li. Surgical Treatment of Huge Primary Retroperitoneal Tumor: A Report of 14 Cases. American Journal of Cancer Prevention. 2016; 4(4):64-69. doi: 10.12691/ajcp-4-4-4.

Correspondence to: Da-xing  Li, Department of General Surgery, The Second People's Hospital of Jiulongpo District, Chong Qing, China. Email: gongjianping11@126.com

Abstract

Objective: To summarize the surgical therapy for huge retroperitoneal tumor. Methods: Retrospective analysis was carried out to study the surgical therapy on 14 patients with huge retroperitoneal tumor. Results: Complete resection in eight cases, partial resection in two cases, combined evisceration in three cases, one biopsy and six cases recurred after surgery. Conclusion: Operative skills and the management during perioperative period are important for the treatment of huge retroperitoneal tumor.

Keywords

References

[1]  Virseda Rodríguez JA, Donate Moreno MJ, Pastor Navarro H, et al. Primary retroperitoneal tumors: review of our 10-year case series. Arch Esp Urol 2010; 63: 13-22.
 
[2]  Ballo MT, Zagars GK, Pollock RE, et al. Retroperitoneal soft tissue sarcoma: An analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys 2007; 67: 158-163.
 
[3]  Tseng WW, Madewell JE, Wei W, et al. Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection? Ann Surg Oncol 2014; 21: 2136-2143.
 
[4]  Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 2010; 10: 249-260.
 
[5]  An JY, Heo JS, Noh JH, et al. Primary malignant retroperitoneal tumors: analysis of a single institutional experience. Eur J Surg Oncol 2007; 33: 376-382.
 
Show More References
[6]  Pisters PWT, O’Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol 2002; 14: 400-405.
 
[7]  Youssef E, Fontanesi J, Mott M, et al. Long-term outcome of combined modality therapy in retroperitoneal and deep-trunk soft-tissue sarcoma: analysis of prognostic factors. Int J Radiat Oncol Biol Phys 2002; 54: 514-519.
 
[8]  Pirayesh A, Chee Y, Helliwell TR, et al. The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2001; 27: 491-497.
 
[9]  Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer 2004; 100: 2448-2455.
 
[10]  Erzen D, Sencar M, Novak J. Retroperitoneal sarcoma: 25 years of experience with aggressive surgical treatment at the Institute of Oncology, Ljubljana. J Surg Oncol 2005; 91: 1-9.
 
[11]  Linehan DC, Lewis JJ, Leung D, Brennan MF. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol Off J Am Soc Clin Oncol 2000; 18: 1637-1643.
 
[12]  Ferrario T, Karakousis CP. Retroperitoneal sarcomas: grade and survival. Arch Surg Chic Ill 1960 2003; 138: 248-251.
 
Show Less References